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Abstract In contrast to the cell-cycle-dependent histone genes, 
replacement histone genes are transcribed independently of DNA 
replication and their expression is upregulated during differ-
entiation. We have investigated the transcriptional regulation of 
the recently characterized human replacement histone gene 
H3.3B. Using reporter gene assays of promoter-luciferase 
gene-constructs, we show that promoter activity largely depends 
on an intact Oct and CRE/TRE element within the proximal 145 
bp of the promoter. DNase I footprinting revealed binding of 
proteins to a 40-bp region covering these two elements. Band 
shift experiments identified binding proteins as Oct-1 and factors 
of the CREB/ATF and AP-1 family, respectively. The un-
expected transcriptional regulation of this replacement histone 
gene is discussed. 
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1. Introduction 
Histones are the primary constituents of eukaryotic chro-
matin. This group of basic proteins consists of five classes 
termed H I , H2A, H2B, H3 and H4. Except H4, these classes 
of nuclear proteins consist of several subtypes [1,2]. Histone 
genes may be subdivided into three major groups. First, rep-
lication-dependent genes are expressed only during S-phase of 
the cell cycle; second, replication-independent histone genes 
encoding replacement histones are also expressed in nondivid-
ing quiescent or terminally differentiated cells and third, tis-
sue-specific histone isotypes that are exclusively expressed in 
the testis of different mammalian species [3,4]. 
H3.3B is a minor component of the chromatin in dividing 
cells but can become relatively abundant in nondividing cells 
[5-8] and adult tissues [9,10], and is expressed in erythroleu-
kemia cells during the precommitment period of differentia-
tion [11]. The expression of this gene is independent from 
D N A replication [7]. Recently, we have characterized the hu-
man replacement histone gene H3.3B [12]. Among the histone 
gene family, the H3.3B gene shows unique features: it con-
tains three introns and three polyadenylation signals and it is 
solitarily located on chromosome 17, outside the known his-
tone gene clusters on chromosome 6 [13,14] and 1 [15] which 
contain the majority of the replication-dependent histone 
genes. 
We have investigated elements of the H3.3B promoter re-
sponsible for the regulation of the H3.3B expression to further 
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the understanding of the differential transcriptional regulation 
of replication-dependent and replacement histone genes. Us-
ing transient transfection assays of deletion constructs of the 
H3.3B promoter linked to a luciferase reporter gene, DNase I 
footprint analysis and band shift experiments, we demonstrate 
that an Oct element and a C R E / T R E motif largely contribute 
to the expression of this gene. This unexpected finding points 
to a fine tuned transcriptional regulation rather than just 
basal expression of this replacement histone gene variant. 
2. Material and methods 
2.1. Probes and promoter constructs 
For transcription of probes used in RNase protection analysis, the 
Nsil/Xbal fragment of the 3'-flanking region of the H3.3B gene (see 
Fig. 1) was subcloned into Bluescript KS. For generation of the luci-
ferase reporter gene constructs, the following H3.3B promoter frag-
ments were cloned into the SmaXIXhol site of the luciferase vector 
pGL3 basic (Promega): the 4.2-kb fragment corresponding to the 
HináYñlSañ fragment of the H3.3B promoter, the 1.2-kb PsñISañ 
fragment, the 586-bp EcoRllSall fragment, the 349-bp BamHllSall 
fragment and the 292-bp HinftlSah fragment (see Fig. 1). The latter 
292-bp H3.3B promoter fragment was used to generate all minor 
constructs by limited exonuclease III digestion using the Double 
Stranded Nested Deletion Kit (Pharmacia) according to the manufac-
turer's instructions. For mutation of the Oct, CRE/TRE, and 
CCAAT-boxes, the 1.2-kb H3.3B promoter construct was subjected 
to site directed mutagenesis using the QuikChange Site-Directed Mu-
tagenesis kit (Stratagene) as described in the manufacturer's manual. 
The correct sequence of all constructs was verified by automated 
DNA sequencing. 
2.2. RNA isolation and RNase protection analysis 
Isolation of total RNA and RNase protection analysis were per-
formed as described previously [4]. Human RNA was kindly provided 
by Dr. E.J. Bellefroid, Université de Liege [16]. 
2.3. Transfection of cells and luminescence detection 
For transfection experiments, HeLa cells (ATCC CCL2) were cul-
tivated in MEM, 10°/, fetal calf serum at 37°C and 5% C0 2 . Trans-
fections were performed as recommended by the DOTAP manual 
(Boehringer Mannheim). 2X10° cells were cultured in 2 ml medium 
and transfected with 2 μg of plasmid DNA and 50 ng pCMVßGAL 
(Clontech) using 12 μΐ DOTAP in 20 mM HEPES pH 7.4 containing 
150 mM NaCl for 17-19 h. After transfection, cells were washed with 
PBS, incubated with 125 μΐ lysis buffer provided with the Galacto-
Light Plus kit (Tropix) and harvested with a rubber policeman. 20 μΐ 
of cell lysate was subjected to measurement of luciferase activity in a 
luminometer using the luciferase assay substrate provided with the 
Luciferase Assay System kit (Promega). For determination of the 
co-transfected ß-galactosidase activity, 10 μΐ of cell lysate was incu-
bated with 66 μΐ reaction buffer provided with the Galacto-Light Plus 
kit for 1 h at room temperature and luminescence was measured in a 
luminometer (AutoLumat LB 953, Berthold) using the accelerator 
provided with the kit. All measurements were performed in duplicates. 
To take into account different transfection efficiencies as well as differ-
ences in the amount of cell lysates subjected to luminescence measure-
ment, the luciferase activity was normalized by the corresponding co-
transfected ß-galactosidase activity corrected by the endogenous ß-
galactosidase activity. The obtained luciferase activities were then ex-
pressed relatively to the activity of the 1.2-kb wild-type construct. 
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2.4. DNase I footprint analysis 
Nuclear extracts were prepared exactly as previously described by 
Dignam et al. [17]. A 230-bp promoter fragment containing the 
TATA, Oct, CRE/TRE and the first two CCAAT-boxes was end-
labeled with [γ-32Ρ]-ΑΤΡ using T4 polynucleotide kinase (MBI Fer-
mentas). 50 000 cpm of the DNA probe was incubated with increasing 
amounts (20-60 μg) of nuclear proteins in 30 μΐ binding buffer con-
taining 20 mM HEPES pH 7.9, 100 mM KC1, 0.2 mM EDTA, 0.5 
mM PMSF, 0.5 mM DTT, 20% (v/v) glycerol and 60 μ^piύ poly(dI-
dC) for 60 min on ice. At the end of the incubation, 200 ng DNase I 
(Boehringer Mannheim) in 10 μΐ 20 mM MgCl2, 60 μg/ml poly(dl-dC) 
was added to the samples with nuclear extracts. Control samples with-
out nuclear proteins were treated in the same way except that the 
amount of added DNase I was 50 ng. The mixture was incubated 
for 90 seconds at room temperature and DNase I digestion was ter-
minated by the addition of 100 μΐ of 20 mM Tris/HCl pH 7.5, 20 mM 
EDTA, 0.4% SDS, 800 μg/ml tRNA and 80 μ^piύ proteinase K. After 
phenol/chloroform extraction and ethanol precipitation, the samples 
were analyzed on a denaturing 8 M urea/5% (v/v) polyacrylamide gel. 
2.5. Band shift experiments 
The following oligonucleotides from the H3.3B promoter were used 
in band shift experiments. H3.3B Oct: 5'-CGTTGGTGTATGCAAA-
TAAGGGTT-3' and H3.3B CRE/TRE: 5'-GGGTTCTATGACG-
CAGAGACGCAG-3'. The CRE and AP-1 consensus oligonucleoti-
des were obtained from Santa Cruz Biotechnology. About 0.01 pmol 
(30000 cpm) of the [y-32P]-ATP-labeled double-stranded oligonucleo-
tide was incubated with 10 μg of nuclear proteins, in the presence or 
absence of unlabeled competitor, in a total volume of 16 μΐ, contain-
ing 10 mM HEPES pH 7.9, 5% (v/v) glycerol, 125 μ^piιΐ poly(dl-dC), 
50 mM KC1, 1 mM EDTA, 1 mM DTT and 0.5 mM PMSF for 30 
min at room temperature. At the end of incubation, 2 μΐ of loading 
buffer with 5% glycerol was added and samples were analyzed on a 
4% non-denaturing polyacrylamide gel. In the supershift analysis, the 
mixture of [7-32P]-ATP-labeled double-stranded oligonucleotide and 
nuclear proteins was further incubated with serial dilutions of an 
Oct-1-specific antibody (Oct-1 supershift reagent, Santa Cruz Biotech-
nology) for 45 min at room temperature and then analyzed by gel 
electrophoresis as described above. 
3. Results 
3.1. Expression of the Human H3.3B Gene 
We have examined the expression of the recently character-
ized human histone gene H3.3B gene using RNase protection 
assay. The probe used in this assay was transcribed from the 
Nsil/Xbal fragment of the 3'-flanking region (see Fig. 1). Fig. 
2 shows that the H3.3B gene is transcribed in several human 
cells and tissues investigated, albeit at different levels. Three 
polyadenylation sites corresponding to three H3.3B mRNA 
species differing in length have been described [12]. The pre-
dominant mRNA of the H3.3B gene appears to be the longest 
1.8-kb transcript and to a lesser extent the smaller 1.4-kb 
transcript. In contrast, we were not able to detect a protected 
fragment corresponding to the shortest transcript of 1.1 kb in 
length (not shown). Since HeLa cells express the H3.3B gene 
at a relatively high rate, we used this cell line to further study 
the mechanism of transcriptional regulation of this gene. 
Fig. 1. Restriction map of the human replacement histone gene 
H3.3B (EMBL accession No. Z48950). Arrow indicates start site of 
transcription, black boxes flanking portions and open boxes inter-
vening sequences. 
Fig. 2. Expression of the human replacement histone gene H3.3B. 
Total RNA from different cell lines and human tissues was sub-
jected to RNase protection assay using a probe from the H3.3B 3' 
flanking region. 
3.2. Identification of promoter elements 
To identify eis acting elements in the H3.3B promoter, 4.2 
kb of the promoter region were cloned proximal to the luci-
ferase reporter gene and a series of 5' ->3' deletion constructs 
were transiently expressed in HeLa cells (Fig. 3). Successive 
deletion of the promoter, taking into account the 6 CCAAT-
boxes, down to the proximal 145-bp fragment did not result in 
a significant decrease in relative luciferase activity. However, 
further deletion of 45 bp led to a drop of the promotor ac-
tivity to basal expression levels (Fig. 3). This 45-bp fragment 
contains a fully conserved Octamer element (ATGCAAAT) 
and a CRE/TRE element with the core motif CGTCA on 
the complementary strand [18-21] located at —105 and 
— 128 relative to the Salí cloning site (see Fig. 1), correspond-
ing to —75 and —93 relative to the start of transcription 
(sequences included in Fig. 4). We then investigated the func-
tional relevance of these two elements within the large 1.2-kb 
promoter context by mutating 4 bases of each element, re-
spectively (Fig. 4). Compared with the 1.2-kb wild-type con-
struct, mutation of the Oct and CRE/TRE element caused a 
25% and 45% reduction of luciferase activity (Fig. 4). Muta-
tion of both elements led to a 70% decrease of reporter gene 
activity, indicating that the Oct and CRE/TRE elements and 
corresponding transcription factors are responsible for nearly 
the entire rate of transcriptional activity of the H3.3B pro-
moter. Since CCAAT boxes have been demonstrated to be 
important for the transcription of replication-dependent his-
tone genes [22,23], we also investigated the function of the 
first two CCAAT boxes of the H3.3B promoter. Mutation 
of these elements did not result in a significant change of 
promoter activity, confirming the results of the deletion stud-
ies, which had shown no effect on promoter activity upon 
successive deletion of the 6 CCAAT boxes (Figs. 3 and 4). 
This suggests different functions of the CCAAT boxes in the 
promoters of replication-dependent and replacement histone 
genes. 
3.3. Binding of nuclear proteins to the proximal H3.3B 
promoter region 
Because the deletion and mutation analysis indicated that 
the major part of the H3.3B promoter activity resides within 
the proximal 145 bp, we performed a DNase I footprint ex-
periment to delineate the binding of /raws-acting factors to 
this region. A DNA fragment of 230 bp, including the prox-
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Fig. 3. Transient expression of H3.3B promoter deletion constructs. The deletion constructs are schematically shown in the left panel. The right 
panel shows the corresponding luciferase activity relative to the 1.2-kb construct. The data are mean and SD values of four experiments. 
imal 145 bp of the H3.3B promoter, was incubated with nu-
clear extracts from HeLa cells and was partially digested with 
DNase I. This resulted in a 40-bp protected region containing 
the Oct and CRE/TRE elements (Fig. 5), whereas the region 
of the first two CCAAT-boxes did not reveal binding of nu-
clear proteins (not shown). This confirmed the results of the 
reporter gene analysis by demonstrating the binding of nu-
clear proteins to the region of the Oct and CRE/TRE ele-
ments of the H3.3B promoter. 
3.4. Identification of binding proteins 
To further specify the nuclear proteins binding to the 40-bp 
region of the proximal H3.3B promoter, we performed band 
shift experiments using two overlapping oligonucleotides 
spanning this region. These oligonucleotides, containing the 
Oct and CRE/TRE element, respectively, were incubated with 
nuclear proteins from HeLa cells. Fig. 6A shows specific bind-
ing of nuclear proteins to the Oct element-containing oligo-
nucleotide, giving rise to a single protein-DNA-complex. Since 
Fig. 4. Transient expression of H3.3B mutation constructs. For details see Fig. 3. The inserted sequence shows the Oct and CRE/TRE element 
and flanking nucleotides in the proximal H3.3B promoter region. Dots indicate positions mutated by site directed mutagenesis. 
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the different species of octamer binding proteins form protein-
DNA-complexes with different electrophoretic mobility [24], 
we conclude that only one type of octamer binding protein 
interacts with the H3.3B Oct element in HeLa cells. Supershift 
experiments using a specific antibody identified the binding 
proteins as Oct-1 (Fig. 6B). The analogous experiment using 
the H3.3B CRE/TRE oligonucleotide resulted in the appear-
ance of three distinct protein-DNA-complexes (Fig. 7A). 
These complexes apparently consist of proteins of the 
CREB/ATF family of transcription factors (lower two bands) 
and of AP-1 (upper band) as shown by co-migration of pro-
tein-DNA-complexes obtained with a CRE and AP-1 consen-
sus oligonucleotide of identical size, respectively (Fig. 7B). 
4. Discussion 
In this paper we show that promoter activity of the human 
replacement histone gene H3.3B essentially depends on two 
elements: a fully conserved octamer element and a CRE/TRE 
element both located within the proximal 145 bp of the pro-
moter. We further demonstrate that the transcription factor 
Oct-1 and proteins of the CREB/ATF and AP-1 family of 
transcription factors are capable of binding to these elements, 
respectively. 
The finding of the octamer box and Oct-1 involved in tran-
scriptional regulation of a replacement histone gene is some-
what surprising, since the Oct element and Oct-1 has been 
implicated in the cell-cycle-dependent transcription of the his-
tone gene H2B [25-27]. It therefore appears likely that addi-
tional factors or flanking sequences must exist which convert 
the same element and corresponding transcription factor into 
Fig. 6. Band shift analysis of nuclear proteins binding to the H3.3B 
octamer element. (A) An oligonucleotide consisting of the H3.3B 
Oct element and flanking sequences was incubated with nuclear ex-
tracts without (—) and in the presence of 10, 40 and 200-fold molar 
excess of specific and unspecific competitor, respectively. (B) Super-
shift analysis of the DNA/protein complexes shown in A using an 
Oct-1 specific antibody in serial dilutions. Arrows indicate DNA/ 
protein (A) and DNA/protein/antibody complexes (B), respectively. 
Fig. 5. DNase I footprint analysis of the proximal H3.3B promoter 
region. Lanes: 1 and 5, control samples without nuclear extract; 
2, 3 and 4, samples incubated with 60, 40 and 20 μg nuclear pro-
teins, respectively; 6, G/A sequencing ladder. The sequence of the 
protected promoter region is given on the right. 
a cell-cycle-dependent element in the case of H2B or into a 
replication independent element as part of the H3.3B pro-
moter. An example for such a selective transactivation of 
Oct-factor-dependent transcription is the B cell coactivator 
Bobl which differentially coactivates octamer sites bound by 
Oct-1-depending on the promoter context [28-30]. 
The second element involved in transcriptional regulation 
of the human H3.3B gene has the sequence TGACGCAG. We 
designated this element as CRE/TRE element because (a) this 
element and flanking sequences is able to bind transcription 
factors of the CREB/ATF and AP-1 family, (b) it contains the 
essential CRE core motif CGTCA on the complementary 
strand [20], and (c) the same TGACGCAG motif has been 
identified as the combined cAMP- and TPA-responsive ele-
ment in the promoter of the human cholecystokinin gene 
[19]. Interestingly, it has been shown that nuclear proteins 
bind to a CRE element of a replication-dependent H3 histone 
gene throughout the cell cycle, suggesting that this element 
facilitates basal transcription of this gene outside the S phase 
[31]. Another function of the CRE/TRE element in the H3.3 B 
promoter could be the coupling of H3.3B expression to on-
going differentiation processes of cells mediated by the protein 
kinase C pathway. Preliminary data show that H3.3B exprés-
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Fig. 7. Band shift analysis of nuclear proteins binding to the H3.3B 
CRE/TRE element. (A) An oligonucleotide consisting of the H3.3B 
CRE/TRE element and flanking sequences was incubated with nu-
clear extracts without (—) and in the presence of 10, 40 and 200-
fold molar excess of specific and unspecific competitor, respectively. 
Arrows indicate the resulting three DNA/protein complexes. (B) Co-
migration of the same three DNA/protein complexes as in A (first 
lane) with DNA/protein complexes formed using nuclear extracts 
and CRE and AP-1 consensus oligonucleotides, respectively. 
sion is indeed upregulated following treatment of cells with 
TPA (Witt et al., unpublished data). 
Comparison of the structure of the H3.3B promoter with 
the promoter of the histone gene ΗΓ, which also belongs to 
the group of replacement histone genes, reveals no homologies 
except the existence of a TATA box and an octamer-like 
element (ATTTGCT) [32]. However, reporter gene assays in 
HeLa cells indicate a function of this Oct-like element only in 
cooperation with other more upstream located elements [32]. 
On the other hand, a retinoic-acid-responsive element appears 
to be of major relevance for the H' promoter activity [32,33], 
which is not contained in the H3.3B promoter. This indicates 
that the transcriptional regulation of these two replacement 
genes involves different cisltrans-acting elements. 
In addition to the H3.3B gene, a H3.3A histone gene exists 
[34]. Both genes encode the same H3.3 histone protein but 
differ in their nucleotide coding sequence and flanking por-
tions. In situ hybridization experiments with mouse testis us-
ing probes derived from cDNA sequences revealed different 
expression patterns of both genes, indicating a basal expres-
sion of the H3.3A gene versus a stage-specific transcription of 
the H3.3B gene. Thus, the H3.3B CRE/TRE element might be 
involved in this specific regulation, since the H3.3A promoter 
is lacking the CRE/TRE site. As yet, the mouse H3.3A and 
H3.3B promoter sequences are unknown. 
In addition to promoter sequences, the 3' end of histone 
mRNAs has been shown to be important in regulating histone 
mRNA levels of replication-dependent histone genes [35]. A 
conserved stem-loop structure contained in all replication-de-
pendent histone mRNAs is important for efficient mRNA 
processing and degradation thereby linking mRNA levels of 
these histone genes to the S-phase of the cell-cycle [36-38]. 
Since the H3.3B mRNA is lacking this conserved stem-loop 
structure and contains a poly-A tail instead, it may be possible 
that basal transcription of the H3.3B gene throughout the 
cell-cycle is just due to the lack of the 3' stem-loop. Experi-
ments using chimeric constructs of the H3.3B gene and a 
replication-dependent gene are in progress to investigate this 
possibility. 
In summary, we have identified an Oct and CRE/TRE ele-
ment as major determinants of the H3.3B promoter activity, 
suggesting that these elements are involved in the DNA rep-
lication independent transcription featured by the human 
H3.3B gene, and these elements may also contribute to the 
increased expression of this gene during differentiation proc-
esses. Experiments are in progress to further study the in-vivo 
function of the CRE/TRE element in regulating the transcrip-
tion of the human replacement histone gene H3.3B. 
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